Results 121 to 130 of about 2,398,742 (264)

Causal knowledge graph analysis identifies adverse drug effects. [PDF]

Bioinformatics
Toonsi S, Schofield PN, Hoehndorf R.
europepmc   +1 more source

Identification of a Shiga toxin A‐derived peptide internalized into Gb3 receptor‐bearing cells via interaction with the Shiga toxin B subunit

FEBS Letters, EarlyView.
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi, João C. Encarnação, Valeria Napolitano, Grzegorz Dubin, Grzegorz Popowicz, Karl Andersson, U. Helena Danielson   +6 more
wiley   +1 more source

Cell-type specific single-cell signatures reveal nephrotoxic drug effects. [PDF]

Comput Struct Biotechnol J
Kuchi A, Cortina JMA, Liu H, Fatapour Y, Berkowitz J, Tatonetti NP.   +5 more
europepmc   +1 more source

A multi-scale digital twin for adiposity-driven insulin resistance in humans: diet and drug effects. [PDF]

Diabetol Metab Syndr, 2023
Herrgårdh T, Simonsson C, Ekstedt M, Lundberg P, Stenkula KG, Nyman E, Gennemark P, Cedersund G.   +7 more
europepmc   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Modeling amyloid plaque turnover dynamics improves characterization of drug effects. [PDF]

Alzheimers Dement (N Y)
van Maanen E, Robey S, Bennacef I, Duffull S, Egan MF, Kennedy ME, Stone JA.   +6 more
europepmc   +1 more source

Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions

FEBS Letters, EarlyView.
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang, Hyo Been Jin, Chang Min Kim, So Yeon Lee, Hyun Ho Park   +4 more
wiley   +1 more source

Early Post-Marketing Safety Profile of Fezolinetant in FAERS: A Disproportionality Analysis With Emphasis on Hepatotoxicity

International Journal of Medical Students
Background: Fezolinetant is a nonhormonal neurokinin-3 receptor antagonist approved for moderate-to-severe vasomotor symptoms of menopause. Recent post-marketing safety communications have raised concern regarding potential liver injury, making early ...
Sofya Sandalova
doaj  

Use of a multi-gene pharmacogenetic panel reduces adverse drug effects. [PDF]

Cell Rep Med, 2023
Cavallari LH, Johnson JA.
europepmc   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source